Want to see MDCX full AI Analyst Report?
MDCX Stock Chart & Stats
$0.37
-$0.01(-3.70%)
At close: 4:00 PM EDT
$0.37
-$0.01(-3.70%)
Day’s Range― - ―
52-Week Range$0.25 - $3.05
Previous CloseN/A
Volume1.03M
Average Volume (3M)1.60M
Market Cap
$15.59M
Enterprise Value$10.89
Total Cash (Recent Filing)$6.37M
Total Debt (Recent Filing)$169.62K
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 20, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding56,658,165
10 Day Avg. Volume1,268,688
30 Day Avg. Volume1,603,994
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-391.45
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside981.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressThe FDA safety review authorization for SKNJCT-005 enables initiation of a registrational Phase 2b study, materially de‑risking the regulatory pathway. This allows the company to generate pivotal clinical data, a durable precursor to potential approval and commercialization.
Near-term LiquidityThe $22.86M secured financing extends runway to fund clinical programs and repay prior debt, providing the capital needed to execute trials and business development. Sustained access to funding is essential for advancing registrational studies over the next 12–18 months.
Modest Reported LeverageReported TTM leverage is modest, and total assets grew materially to support R&D investment. A lower leverage ratio provides short-term financial flexibility and reduces immediate bankruptcy risk, helping the company continue clinical development while seeking value inflection points.
Bears Say
High Cash BurnSustained, large operating cash outflows without revenue mean the business will remain dependent on external capital. Continued high burn makes multi‑round financing likely, elevating dilution risk and constraining long‑term investment prioritization until commercial revenues emerge.
Pre‑Revenue, Widening LossesThe company has no product revenue and mounting net losses, which undermines operating sustainability and increases the time needed to reach profitability. Until clinical assets progress to commercialization, negative earnings will pressure cash needs and strategic flexibility.
Financing Terms & Listing RiskOnerous financing covenants and potential structured redemptions raise cash‑flow and control risks. Combined with a Nasdaq compliance deadline, the company faces pressure to execute quickly or raise additional capital, increasing likelihood of dilutive or disruptive measures.
Medicus Pharma Ltd News
MDCX FAQ
What was Medicus Pharma Ltd’s price range in the past 12 months?
Medicus Pharma Ltd lowest stock price was $0.25 and its highest was $3.05 in the past 12 months.
What is Medicus Pharma Ltd’s market cap?
Medicus Pharma Ltd’s market cap is $15.59M.
When is Medicus Pharma Ltd’s upcoming earnings report date?
Medicus Pharma Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 18 days.
How were Medicus Pharma Ltd’s earnings last quarter?
Medicus Pharma Ltd released its earnings results on May 14, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.192 by -$0.118.
Is Medicus Pharma Ltd overvalued?
According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued.
Does Medicus Pharma Ltd pay dividends?
Medicus Pharma Ltd does not currently pay dividends.
What is Medicus Pharma Ltd’s EPS estimate?
Medicus Pharma Ltd’s EPS estimate is -0.13.
How many shares outstanding does Medicus Pharma Ltd have?
Medicus Pharma Ltd has 56,658,165 shares outstanding.
What happened to Medicus Pharma Ltd’s price movement after its last earnings report?
Medicus Pharma Ltd reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.192. Following the earnings report the stock price went down -10.682%.
Which hedge fund is a major shareholder of Medicus Pharma Ltd?
Currently, no hedge funds are holding shares in MDCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicus Pharma Ltd
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
MDCX Stock 12 Month Forecast
Average Price Target
$4.00
▲(981.08% Upside)
Technical Analysis
Ovid Therapeutics
―
Jasper Therapeutics
―
Cognition Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
0.48% Insiders
<0.01% Mutual Funds
3.00% Other Institutional Investors
96.50% Public Companies and
Individual Investors